Methods: A retrospective database analysis was conducted and individuals with MSD's (ICD-9-CM codes 274.00; 710.00-738.00) were identified. Dependent variables were total health care and other service category expenditures. The study utilized descriptive and regression analyses.
Results: In 2007, the national prevalence of MSD's was 33 million with incremental costs of $886.49 per person. The inpatient expenditures ($33,461.85) were the highest cost component in MSD's and the predictors of total health care expenditures were age, marital status, and presence of the disease condition.
Conclusion: The systematic assessment of MSD's and their associated incremental costs to the society is essential in increasing the awareness of decision makers to implement intervention strategies that are effective in lowering the disease incidence and in reducing the overall cost of disease management.","abstract_html":"Objective: To estimate the national prevalence and direct incremental expenditures of musculoskeletal disorders (MSD's) using the 2007 Medical Expenditure Panel Survey data.</p><p> Methods: A retrospective database analysis was conducted and individuals with MSD's (ICD-9-CM codes 274.00; 710.00-738.00) were identified. Dependent variables were total health care and other service category expenditures. The study utilized descriptive and regression analyses.</p><p> Results: In 2007, the national prevalence of MSD's was 33 million with incremental costs of $886.49 per person. The inpatient expenditures ($33,461.85) were the highest cost component in MSD's and the predictors of total health care expenditures were age, marital status, and presence of the disease condition. </p><p> Conclusion: The systematic assessment of MSD's and their associated incremental costs to the society is essential in increasing the awareness of decision makers to implement intervention strategies that are effective in lowering the disease incidence and in reducing the overall cost of disease management.","abstract_has_math":true,"creators":["Atreja, Nipun"],"institution":null,"degree_name":"MS","degree_level":"Immediate Access","degree_discipline":"Pharmacy Administration","degree_department":null,"school":null,"contributors":["Khalid M. Kamal","Vincent J. Giannetti","Gibbs Kanyongo"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2012,"date_issued":"2012-01-01T08:00:00Z","date_published":"2012-01-01T08:00:00Z","updated_at":"2026-07-24T02:09:20Z","subjects":["Incremental health care expenditures","Medical Expenditures Panel Survey","MEPS","MSD's","Musculoskeletal disorders","Retrospective analysis"],"languages":["English"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://dsc.duq.edu/etd/277","outbound_label":"Repository record","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Khalid M. Kamal","Vincent J. Giannetti","Gibbs Kanyongo"]},{"key":"dc:creator","label":"Author","values":["Atreja, Nipun"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2018-08-03T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Pharmacy Administration"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Immediate Access"]},{"key":"thesis:degree_name","label":"Degree Name","values":["MS"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Incremental health care expenditures","Medical Expenditures Panel Survey","MEPS","MSD's","Musculoskeletal disorders","Retrospective analysis"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["English"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://dsc.duq.edu/etd/277"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Objective: To estimate the national prevalence and direct incremental expenditures of musculoskeletal disorders (MSD's) using the 2007 Medical Expenditure Panel Survey data.
Methods: A retrospective database analysis was conducted and individuals with MSD's (ICD-9-CM codes 274.00; 710.00-738.00) were identified. Dependent variables were total health care and other service category expenditures. The study utilized descriptive and regression analyses.
Results: In 2007, the national prevalence of MSD's was 33 million with incremental costs of $886.49 per person. The inpatient expenditures ($33,461.85) were the highest cost component in MSD's and the predictors of total health care expenditures were age, marital status, and presence of the disease condition.
Conclusion: The systematic assessment of MSD's and their associated incremental costs to the society is essential in increasing the awareness of decision makers to implement intervention strategies that are effective in lowering the disease incidence and in reducing the overall cost of disease management."]},{"key":"dc:title","label":"Title","values":["Medication Expenditure and Resource Utilization Among Patients with Musculoskeletal Disorders: Analysis of 2007 Medical Expenditure Panel Survey Data"]}]}],"canonical_facts":{"dc:contributor":["Khalid M. Kamal","Vincent J. Giannetti","Gibbs Kanyongo"],"dc:creator":["Atreja, Nipun"],"dc:date.available":["2018-08-03T07:00:00Z"],"dc:description.abstract":["Objective: To estimate the national prevalence and direct incremental expenditures of musculoskeletal disorders (MSD's) using the 2007 Medical Expenditure Panel Survey data.
Methods: A retrospective database analysis was conducted and individuals with MSD's (ICD-9-CM codes 274.00; 710.00-738.00) were identified. Dependent variables were total health care and other service category expenditures. The study utilized descriptive and regression analyses.
Results: In 2007, the national prevalence of MSD's was 33 million with incremental costs of $886.49 per person. The inpatient expenditures ($33,461.85) were the highest cost component in MSD's and the predictors of total health care expenditures were age, marital status, and presence of the disease condition.
Conclusion: The systematic assessment of MSD's and their associated incremental costs to the society is essential in increasing the awareness of decision makers to implement intervention strategies that are effective in lowering the disease incidence and in reducing the overall cost of disease management."],"dc:identifier":["https://dsc.duq.edu/etd/277"],"dc:language":["English"],"dc:subject":["Incremental health care expenditures","Medical Expenditures Panel Survey","MEPS","MSD's","Musculoskeletal disorders","Retrospective analysis"],"dc:title":["Medication Expenditure and Resource Utilization Among Patients with Musculoskeletal Disorders: Analysis of 2007 Medical Expenditure Panel Survey Data"],"thesis:degree_discipline":["Pharmacy Administration"],"thesis:degree_level":["Immediate Access"],"thesis:degree_name":["MS"]},"updated_at":"2026-07-24T02:09:20Z"}